Jefferies Maintains Buy on Tilray Brands, Raises PT to $2
PorAinvest
lunes, 25 de agosto de 2025, 10:03 am ET1 min de lectura
TLRY--
The price target increase reflects Jefferies' belief that the potential rescheduling of cannabis from Schedule I to Schedule III in the United States represents a significant federal policy shift that could benefit Tilray. While this change falls short of full legalization, it marks progress as Congress reviews bills related to banking, access, and reform in the cannabis sector. Rescheduling could also provide secondary benefits such as lower taxes and easier research opportunities for cannabis companies.
Tilray is identified as "the biggest potential beneficiary" of these regulatory developments, according to Jefferies. However, the company could face intensifying headwinds in its alcohol business. Despite these challenges, Tilray maintains a moderate debt level and strong liquidity, with current assets exceeding short-term obligations by 2.46x.
In other recent news, Tilray Brands Inc. has applied for an extension to meet Nasdaq’s minimum share price requirements. The company is exploring several options to address this issue, including a potential reverse stock split that would need stockholder approval. Tilray’s share price has been trading below the $1 minimum required by Nasdaq for continued listing. Meanwhile, the company saw a significant boost in its stock price, jumping 17.7%, amid reports that President Donald Trump is considering reclassifying marijuana as a less dangerous drug.
Analysts have given Tilray a consensus rating of "Hold" from five analysts, with one analyst issuing a buy rating and four holding the stock. The average 12-month target price among analysts is $1.9167. CEO Irwin D. Simon recently purchased 165,000 shares at $0.61 per share, increasing his ownership to approximately $2.4 million.
Tilray Brands' latest earnings report revealed a positive EPS of $0.02, exceeding expectations, despite falling short on revenue projections. The company's stock has been trading up 3.6% recently, hitting $1.15.
References:
[1] https://www.investing.com/news/analyst-ratings/tilray-stock-price-target-raised-to-200-from-150-at-jefferies-93CH-4208417
[2] https://www.marketbeat.com/instant-alerts/tilray-brands-inc-nasdaqtlry-given-average-recommendation-of-hold-by-analysts-2025-08-23/
Jefferies Maintains Buy on Tilray Brands, Raises PT to $2
In a recent update, Jefferies has raised its price target on Tilray Brands Inc. (NASDAQ:TLRY) from $1.50 to $2.00 while maintaining a Buy rating on the company's stock. This move comes amidst significant market developments and regulatory shifts in the cannabis industry.The price target increase reflects Jefferies' belief that the potential rescheduling of cannabis from Schedule I to Schedule III in the United States represents a significant federal policy shift that could benefit Tilray. While this change falls short of full legalization, it marks progress as Congress reviews bills related to banking, access, and reform in the cannabis sector. Rescheduling could also provide secondary benefits such as lower taxes and easier research opportunities for cannabis companies.
Tilray is identified as "the biggest potential beneficiary" of these regulatory developments, according to Jefferies. However, the company could face intensifying headwinds in its alcohol business. Despite these challenges, Tilray maintains a moderate debt level and strong liquidity, with current assets exceeding short-term obligations by 2.46x.
In other recent news, Tilray Brands Inc. has applied for an extension to meet Nasdaq’s minimum share price requirements. The company is exploring several options to address this issue, including a potential reverse stock split that would need stockholder approval. Tilray’s share price has been trading below the $1 minimum required by Nasdaq for continued listing. Meanwhile, the company saw a significant boost in its stock price, jumping 17.7%, amid reports that President Donald Trump is considering reclassifying marijuana as a less dangerous drug.
Analysts have given Tilray a consensus rating of "Hold" from five analysts, with one analyst issuing a buy rating and four holding the stock. The average 12-month target price among analysts is $1.9167. CEO Irwin D. Simon recently purchased 165,000 shares at $0.61 per share, increasing his ownership to approximately $2.4 million.
Tilray Brands' latest earnings report revealed a positive EPS of $0.02, exceeding expectations, despite falling short on revenue projections. The company's stock has been trading up 3.6% recently, hitting $1.15.
References:
[1] https://www.investing.com/news/analyst-ratings/tilray-stock-price-target-raised-to-200-from-150-at-jefferies-93CH-4208417
[2] https://www.marketbeat.com/instant-alerts/tilray-brands-inc-nasdaqtlry-given-average-recommendation-of-hold-by-analysts-2025-08-23/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios